NCT06026748进行中（未招募）1 期
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of XJ103 in Chinese Healthy Subjects
Starmab biologics（Shanghai）Co,.ltd1 个研究点 分布在 1 个国家目标入组 38 人开始时间: 2023年9月12日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 38
- 试验地点
- 1
- 主要终点
- Incidence of any adverse events that occurred among all subjects during the clinical trial
研究概览
简要总结
This is a randomized, double-blind, placebo-parallel intervention clinical study that will include approximately 38 healthy subjects based on inclusion and exclusion criteria. Subjects will be assigned to one of four different dosage cohorts. Subjects in each cohort will randomly be given experimental drug or a placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age 18 through 45 years at screening.
- •Male weight ≥ 50.0 kg, female weight ≥ 45.0 kg, and body mass index (BMI) within the range of 19.0 to 26.0 kg/m2 (including critical values).
- •The subjects have no pregnancy plan and voluntarily avoid pregnancy from signing the informed consent form until the end of the trail.
- •Healthy on the basis of physical examination and medical and surgical history and twelve-lead electrocardiogram (ECG) without clinically relevant abnormalities.
- •Written informed consent and any locally required authorization (eg, HIPAA) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.
排除标准
- •Subjects with any abnormalities of respiratory system, circulatory system, digestive system, nervous system, skeletal muscle system, blood and lymphatic system, immune system and endocrine system.
- •History of allergy to drugs or biological products or individuals with allergic constitution.
- •Acute infection within 4 weeks prior to study entry.
- •Suffer from diseases caused by streptococcus pneumoniae within 1 year prior to study entry, such as pneumococcal pneumonia, pneumococcal meningitis, etc.
- •Receipt of any standard vaccine against streptococcus pneumoniae before the study period.
- •Receipt of any standard vaccine within 4 weeks prior to investigational product dosing or plan to vaccinate during the study period.
- •Receipt of any major surgery within 3 months prior to the start of the trial, or have not recovered from surgery, or plan to have a surgical during the trial.
- •Those who cannot tolerate venipuncture, or have a history of injector and blood sickness, or are not suitable for venous blood collection.
- •Subjects with a history of drug abuse or drug use, or those with positive urine drug screening.
- •Blood donation or massive blood loss (> 200 mL) within three months prior to screening or plan to donate blood, receive blood transfusions, or use blood products during the trial period or within 1 month after the end of the trial.
- •Pregnant or lactating women.
- •Use of any prescription drugs, over-the-counter drugs, vitamin products or herbal medicines within 14 days prior to screening.
- •Smoke more than 5 cigarettes per day within three months prior to screening.
- •Frequent drinkers in the three months before screening, i.e. those who drink more than or equal to 14 units of alcohol per week on average (1 unit=17.7 ml ethanol, 1 unit=354 ml beer with 5% alcohol, 44.25 ml spirits with 40% alcohol, or 147.5 ml wine with 12% alcohol), or those who do not agree to ban alcohol during the study period.
- •Evidence of infection with HBV, hepatitis C, HIV, or syphilis.
- •Positive alcohol breath test.
- •Subjects with special dietary requirements or cannot accept a unified diet.
- •Participation in other clinical trials within three months prior to enrollment or plan to participate in other clinical trials during this period.
- •Any other factors evaluated by investigators that patients cannot be enrolled.
研究组 & 干预措施
XJ103 Injection
Experimental
Participants will receive a single dose of XJ103 intravenously.
干预措施: XJ103 Injection (Drug)
Placebo
Placebo Comparator
Participants will receive a single dose of placebo intravenously.
干预措施: Placebo (Drug)
结局指标
主要结局
Incidence of any adverse events that occurred among all subjects during the clinical trial
时间窗: From the time of informed consent through 358 days post dose.
次要结局
- Area Under the Serum Concentration Time Curve from Time Zero to Infinity (AUC [0-Infinity])(From Day 1 through 358 days post dose.)
- Elimination Rate Constant (Kel)(From Day 1 through 358 days post dose.)
- Proportion of Participants Positive for Anti-drug Antibodies (ADA)(From Day 1 through 358 days post dose.)
- Maximum Observed Serum Concentration (Cmax)(From Day 1 through 358 days post dose.)
- Terminal Phase Elimination Half-life (t1/2)(From Day 1 through 358 days post dose.)
- Mean Residence Time (MRT)(From Day 1 through 358 days post dose.)
- Apparent Volume of Distribution (Vd)(From Day 1 through 358 days post dose.)
- Percentage of Area Under the Serum Concentration Time Curve That Has Been Derived After Extrapolation (AUC_% Extrap)(From Day 1 through 358 days post dose.)
- Area Under the Serum Concentration Time Curve from Time Zero to Last Measurable Concentration (AUC [0-Last])(From Day 1 through 358 days post dose.)
- Apparent Serum Clearance (CL)(From Day 1 through 358 days post dose.)
- Titer Range of Anti-drug Antibodies (ADA)(From Day 1 through 358 days post dose.)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A Phase I Study of XJ101 in Chinese Healthy SubjectsStaphylococcus Aureus Bloodstream InfectionNCT06014736Starmab biologics（Shanghai）Co,.ltd38
已完成
1 期
A Phase I Study of SHEN26 Capsule in Healthy ParticipantsHealthy ParticipantsNCT05504746Shenzhen Kexing Pharmaceutical Co., Ltd.86
Unknown
1 期
A Phase I Single- and Multiple- Ascending Dose and Food Effect Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7535 in Healthy SubjectsHealthy SubjectsNCT05347758Shandong Suncadia Medicine Co., Ltd.106
已完成
1 期
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics ，Pharmacodynamics of Oral SHR2150 in Healthy SubjectsHIV-1 InfectionNCT04802811Jiangsu HengRui Medicine Co., Ltd.37
已完成
1 期
Safety, Tolerability, Pharmacokinetics(PK), Pharmacodynamics(PD) and Food Effect of HRS9950 in Healthy and CHB SubjectsChronic Hepatitis bNCT04464733Jiangsu HengRui Medicine Co., Ltd.146